166 related articles for article (PubMed ID: 38316642)
21. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
23. Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease.
Wang QY; Li Y; Liang ZY; Yin Y; Liu W; Wang Q; Dong YJ; Sun YH; Xu WL; Ren HY
Cancer Manag Res; 2019; 11():10195-10203. PubMed ID: 31824191
[TBL] [Abstract][Full Text] [Related]
24. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
[TBL] [Abstract][Full Text] [Related]
25. Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission.
Yao W; Chu X; Fang X; Zhu X; Tang B; Wan X; Geng L; Tong J; Song K; Zhang X; Qiang P; Sun G; Liu H; Sun Z
J Clin Pharm Ther; 2020 Dec; 45(6):1372-1381. PubMed ID: 33010180
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
27. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
[TBL] [Abstract][Full Text] [Related]
28. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of decitabine pretreatment-based allogeneic hematopoietic stem cell transplantation affecting transplantation-related complications and prognosis in patients with malignant hematological disease.
Li L; Zhao Z; Li X
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):69-75. PubMed ID: 38279480
[TBL] [Abstract][Full Text] [Related]
31. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
32. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
33. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
Castro-Malaspina H; Jabubowski AA; Papadopoulos EB; Boulad F; Young JW; Kernan NA; Perales MA; Small TN; Hsu K; Chiu M; Heller G; Collins NH; Jhanwar SC; van den Brink M; Nimer SD; O'Reilly RJ
Biol Blood Marrow Transplant; 2008 Apr; 14(4):458-68. PubMed ID: 18342789
[TBL] [Abstract][Full Text] [Related]
34. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
[TBL] [Abstract][Full Text] [Related]
35. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
36. Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes Demonstrates Long Term Survival, Results from Australia and New Zealand Transplant and Cellular Therapies.
Abadir E; Othman J; Kwan J; Gottlieb DJ; Kennedy GA; Bajel A; Doocey R; Perera T; Watson AM; Bardy PG; Greenwood M; Curtis DJ; Tran S; Moore J; Hamad N
Transplant Cell Ther; 2024 Mar; 30(3):334.e1-334.e7. PubMed ID: 38029962
[TBL] [Abstract][Full Text] [Related]
37. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
38. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
39. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Tazoe K; Harada N; Makuuchi Y; Kuno M; Takakuwa T; Okamura H; Hirose A; Nakamae M; Nishimoto M; Nakashima Y; Koh H; Hino M; Nakamae H
Ann Hematol; 2024 Jun; 103(6):2059-2072. PubMed ID: 38662207
[TBL] [Abstract][Full Text] [Related]
40. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
